Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

被引:10
作者
Szucs, Thomas D. [2 ]
Largeron, Nathalie [3 ]
Dedes, Konstantin J. [4 ]
Rafia, Rachid [1 ]
Benard, Steve [1 ]
机构
[1] Steve Consultants, F-69001 Lyon, France
[2] Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland
[3] Sanofi Pasteur MSD, Lyon, France
[4] Univ Zurich Hosp, Dept Obstet & Gynecol, CH-8091 Zurich, Switzerland
关键词
cervical cancer screening; cost-effectiveness; Human Papillomavirus; Switzerland; vaccination;
D O I
10.1185/030079908X297826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus (HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 infections. The objective of this study was to explore the cost-effectiveness of an HPV vaccination in Switzerland. Design and methods: A Markov model of the natural history of HPV infection was adapted to the Swiss context and followed a hypothetical cohort of 41200 girls aged 11 years over their lifetime. Main epidemiological and economic parameters were extracted from the literature. Two strategies were compared: conventional cytological screening only and HPV vaccination followed by conventional cytological screening. A coverage rate of 80% was used and the vaccine was assumed to provide a lifelong protection. Analyses were performed from the direct health care cost perspective including only direct medical costs. Results: Compared to screening only, adding a quadrivalent HPV vaccine could prevent over lifetime 62% of cervical cancers and related deaths, 19% of Cervical Intraepithelial Neoplasia (CIN 1), 43% of CIN 2, 45% of CIN 3 and 66% of genital warts per cohort. Incremental cost-effectiveness ratios (ICER) were estimated to be CHF 45 008 per Life Year Gained (LYG) and CHF 26 005 per Quality Adjusted Life Year (QALY) gained. Sensitivity analyses demonstrated that the ICER was robust to all parameters, but was most sensitive to the need for a booster and discount rates. Conclusions: Compared to commonly accepted standard thresholds in Europe and other vaccination strategies implemented in Switzerland, adding a quadrivalent HPV vaccine alongside the current cervical cancer screening programme is likely to be cost-effective in Switzerland.
引用
收藏
页码:1473 / 1483
页数:11
相关论文
共 50 条
[21]   Cost-effectiveness of Cervical Cancer Prevention [J].
Esselen, Katharine M. ;
Feldman, Sarah .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2013, 56 (01) :55-64
[22]   Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain [J].
Ibanez, R. ;
Mareque, M. ;
Granados, R. ;
Andia, D. ;
Garcia-Rojo, M. ;
Quilez, J. C. ;
Oyaguez, I. .
BMC WOMENS HEALTH, 2021, 21 (01)
[23]   Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain [J].
R. Ibáñez ;
M. Mareque ;
R. Granados ;
D. Andía ;
M. García-Rojo ;
J. C. Quílez ;
I. Oyagüez .
BMC Women's Health, 21
[24]   A Systematic Review on Cost-Effectiveness Studies Evaluating HPV Self-Testing for Cervical Cancer Screening [J].
Hallsson, Lara Run ;
Haaf, Leonie Heloiese ;
Hillemanns, Peter ;
Jentschke, Matthias ;
Siebert, Uwe ;
Sroczynski, Gaby .
MEDICAL DECISION MAKING, 2024, 44 (02) :NP217-NP219
[25]   Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis [J].
Bresse, Xavier ;
Goergen, Christoph ;
Prager, Bernhard ;
Joura, Elmar .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) :269-281
[26]   Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore [J].
Phua, Lee Cheng ;
Choi, Horace C. W. ;
Wu, Joseph ;
Jit, Mark ;
Low, Jeffrey ;
Ng, Kwong ;
Pearce, Fiona ;
Hall, Cameron ;
Aziz, Mohamed Ismail Abdul .
VACCINE, 2021, 39 (16) :2262-2270
[27]   Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy [J].
Mennini, Francesco Saverio ;
Bonanni, Paolo ;
Bianic, Florence ;
de Waure, Chiara ;
Baio, Gianluca ;
Plazzotta, Giacomo ;
Uhart, Mathieu ;
Rinaldi, Alessandro ;
Largeron, Nathalie .
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
[28]   Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy [J].
Francesco Saverio Mennini ;
Paolo Bonanni ;
Florence Bianic ;
Chiara de Waure ;
Gianluca Baio ;
Giacomo Plazzotta ;
Mathieu Uhart ;
Alessandro Rinaldi ;
Nathalie Largeron .
Cost Effectiveness and Resource Allocation, 15
[29]   Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis [J].
Choi, Horace C. W. ;
Leung, Kathy ;
Chan, Karen K. L. ;
Bai, Yuan ;
Jit, Mark ;
Wu, Joseph T. T. .
BMC MEDICINE, 2023, 21 (01)
[30]   Cost-effectiveness of a cervical screening program with human papillomavirus vaccine [J].
Sopina, Elizaveta ;
Ashton, Toni .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2011, 27 (04) :290-297